Table 1.
General, hormonal and treatment characteristics in patients with acromegaly
| Males | Females | |||||||
| G1 n=6 |
G2 n=16 |
G3 n=18 |
G4 n=16 |
G1 n=15 |
G2 n=26 |
G3 n=18 |
G4 n=31 |
|
| GH (mean±SD) | 1.92±1.57 | 2.61±1.26 | 28.46±25.49 | 31.58±31.26 | 3.39±2.3 | 2.59±1.66 | 27.38±32.3 | 18.24±16.14 |
| IGF1 (mean±SD) | 24.85±14.5 | 24.21±10.8 | 79.02±33.3 | 86.46±46.4 | 26.6±14.09 | 22.64±11 | 75.5±31.8 | 64.5±36.6 |
| Age yrs (mean±SD) | 48.17±14.8 | 53.2±14 | 46.6±13 | 49.3±14.4 | 42.3±13.5 | 57.5±6.3 | 37.4±12 | 55.4±7 |
| Weight kgs (mean±SD) | 87.8±12.1 | 93.1±18.8 | 97.6±24.4 | 96.1±17.8 | 79.1±17.7 | 80.1±13.8 | 71.9±10.4 | 82.2±16.7 |
| Height cm (mean±SD) | 175.2±5.4 | 175.6±8.7 | 180.3±12.3 | 179.1±10.6 | 168.0±6.8 | 161.7±6.7 | 166.8±5.8 | 163.4±6 |
| Treatment | ||||||||
| TSA (n) | 4 | 11 | 2 | 4 | 6 | 12 | 3 | 6 |
| TSA+Ro (n) | 2 | 2 | 0 | 0 | 3 | 6 | 1 | 3 |
| Primary DA (n) | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
| TSA+DA (n) | 0 | 2 | 2 | 3 | 3 | 2 | 4 | 10 |
| TSA+SSA (n) | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| TSA+DA+SSA (n) | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| TSA+Ro+ DA (n) | 0 | 0 | 0 | 1 | 2 | 6 | 2 | 2 |
| TSA+Ro+SSA (n) | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 0 |
| TSA+Ro+DA+SSA (n) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| AH controlled under therapy (n) | 11 | 11 | 20 | 24 | ||||
G1 - normotensive patients with controlled disease; G2 - hypertensive patients with controlled disease; G3 - normotensive patients with active disease; G4 - hypertensive patients with active disease; n – number of patients; GH – growth hormone, measured in mIU/L, conversion factor to ng/ml is 3; IGF-1 – insulin-like growth factor 1, measured in nmol/L; yrs- years; kgs – kilograms; cm – centimeters; TSA – transsphenoidal adenomectomy; Ro – radiotherapy; DA – Dopamine agonist; SSA – somatostatin analog; AH – arterial hypertension.